Overview

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Status:
Completed

Trial end date:
2018-12-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of S 95005 in patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to standard chemotherapies in terms of Progression-Free Survival rate at 2 months in the Russian population.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

ADIR, a Servier Group company

Treatments:

Trifluridine